Alemtuzumab is an anti-CD52 monoclonal antibody that has also been shown to produce hematological and clinical (no cytogenetic) responses in CEL-NOS but is reserved for patients with refractory disease because of significant adverse effects [18]. The gene discussed is CD52; the disease is Chronic Eosinophilic Leukemia, Not Otherwise Specified.